Brain Imaging for HIV-Associated Thinking and Mood Disorders
|ClinicalTrials.gov Identifier: NCT01692236|
Recruitment Status : Terminated
First Posted : September 25, 2012
Last Update Posted : June 19, 2018
- Human immunodeficiency virus (HIV) infection appears to cause problems with blood vessel function. These problems may add to some thinking and mood disorders found in people with HIV infection. Researchers want to evaluate HIV infected patients to see if blood vessel function contributes to thinking and mood disorders, such as early dementia and depression. To do so, they will compare study results between people with and people without HIV infection.
- To compare the thickness of blood vessel walls between people with and without HIV infection.
- To study the relationship between blood vessel thickness and thinking and mood disorders.
- Individuals between 25 and 55 years of age who have HIV infection.
- Healthy individuals between 25 and 55 years of age.
- Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected.
- Participants will have imaging studies of the brain and major blood vessels in the head and neck.
- Participants will also have neuropsychological testing. These tests will look at memory, learning and thinking ability, attention, and mood.
- Participants will have the option of coming back for repeat blood tests every six months and repeat imaging studies and neuropsychological tests every year, over 1- 4 years period.
|Condition or disease|
|Human Immunodeficiency Virus Neurocognitive Impairment|
|Study Type :||Observational|
|Actual Enrollment :||84 participants|
|Official Title:||Neurovascular Magnetic Resonance Imaging in the Assessment of HIV-Associated Neurocognitive Disorders|
|Study Start Date :||September 13, 2012|
|Study Completion Date :||April 4, 2018|
- Neuropsychologic testing scores [ Time Frame: 1-6 years ]
- Serum biomarkers of cardiovascular disease and inflammation [ Time Frame: 1-6 years ]
- MRI brain and vascular findings [ Time Frame: 1-6 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01692236
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Avindra Nath, M.D.||National Institute of Neurological Disorders and Stroke (NINDS)|